Clinical Trials Browser

Phase NA × olaparib × Clear all

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

Neoplasms

NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Phase NA Completed

Ovarian Neoplasms